Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Anne J Lee1,2, Peter McCluskey2,31Manchester Royal Eye Hospital, Manchester, UK; 2University of Sydney, Sydney, Australia; 3Sydney Eye Hospital, Sydney, AustraliaAbstract: Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne J Lee, Peter McCluskey
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/56f2717d0d004d79b303802ee29f4659
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:56f2717d0d004d79b303802ee29f4659
record_format	dspace
spelling	oai:doaj.org-article:56f2717d0d004d79b303802ee29f46592021-12-02T00:33:04ZClinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension1177-54671177-5483https://doaj.org/article/56f2717d0d004d79b303802ee29f46592010-07-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-and-differential-effects-of-prostaglandin-analogs-in--a4812https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Anne J Lee1,2, Peter McCluskey2,31Manchester Royal Eye Hospital, Manchester, UK; 2University of Sydney, Sydney, Australia; 3Sydney Eye Hospital, Sydney, AustraliaAbstract: Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2a. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOP-lowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1- to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.Keywords: prostaglandin analog, glaucoma, ocular hypertension, latanoprost, bimatoprost, travoprost Anne J LeePeter McCluskeyDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 741-764 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Anne J Lee Peter McCluskey Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
description	Anne J Lee1,2, Peter McCluskey2,31Manchester Royal Eye Hospital, Manchester, UK; 2University of Sydney, Sydney, Australia; 3Sydney Eye Hospital, Sydney, AustraliaAbstract: Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2a. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOP-lowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1- to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.Keywords: prostaglandin analog, glaucoma, ocular hypertension, latanoprost, bimatoprost, travoprost
format	article
author	Anne J Lee Peter McCluskey
author_facet	Anne J Lee Peter McCluskey
author_sort	Anne J Lee
title	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
title_short	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
title_full	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
title_fullStr	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
title_full_unstemmed	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
title_sort	clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/56f2717d0d004d79b303802ee29f4659
work_keys_str_mv	AT annejlee clinicalutilityanddifferentialeffectsofprostaglandinanalogsinthemanagementofraisedintraocularpressureandocularhypertension AT petermccluskey clinicalutilityanddifferentialeffectsofprostaglandinanalogsinthemanagementofraisedintraocularpressureandocularhypertension
_version_	1718403675416690688

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Ejemplares similares